Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALILEO-2
2024-511172-33-00Phase 2Authorised
- Sponsor
- Spur Therapeutics
- Start
- Apr 2024
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of avigbagene parvec in Gaucher disease type 1 (GD1), sponsored by Spur Therapeutics. Primary endpoint: Incidence of treatment-emergent adverse events (TEAEs), including dose-limiting toxicities (DLTs). Planned start Apr 2024; status: authorised.
02
Drugs
avigbagene parvec
03
Conditions
Gaucher disease type 1 (GD1)
Beyond the preview
Go deeper on 2024-511172-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511172-33-00.